10 Results
October/November 2009
- Translational Medicine Perspectives in Drug Discovery and Development-PART VI: New Environment, New Challenges, New Solutions
Salvatore Alesci, Ph.D., Robin Fears Ph.D., Charles Gombar Ph.D., Charles Dormer, & Roy Baranello Giora Z Feuerstein MD, MSc, FAHA AVP and Head, Discovery Translational Medicine and TMRC, Scotland Wyeth Research, PA
- Molecular Biomarkers for Individualized Cancer Management: Current and Challenges
Jonathan B. Overdevest, MSTP Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center Jae K. Lee, PhD. Department of Public Health Sciences, University of Virginia Health Sciences Center
- Synergistic Use of Lead Discovery Technologies in Fragment-Based Drug Design: Strategies and Tactics
Igor Mochalkin, Ph.D. Computational Sciences, Pfizer,Inc. Veerabahu Shanmugasundaram, Ph.D. Head of the Computational Chemistry Group, Pfizer,Inc.
- Fluorescence Imaging Methods for Monitoring GPCR/G-protein Signaling in Single Live Cells
Tian Jin, Ph.D. Sr. Investigator, Chief, Chemotaxis Signal Section, LIG, NIAID, NIH
- Flow Cytometry 2010
David Gebhard, Head of Cellular Imaging and Cytometry Laboratory, Translational Biomarker and Mechanistic Biology Group, Pfizer, Inc.
- Cancer Stem Cells: Lessons from Acute Myeloid Leukemia
Dominique Bonnet, Ph.D., Head of Haematopoetic Stem Cell Group, Cancer Research UK
- High-Content Analysis in Predictive Pharmacology and Toxicology
Jinghai James Xu, Ph.D., Director of Automated Biotechnology, Merck & Co., Inc.
- Utility of microRNAs for the Diagnosis and Prognosis of Patients with Solid Tumors
Greg M. Arndt, Ph.D. Drug Discovery Manager, Children’s Cancer Institute Australia Mitch Raponi, Ph.D. Principal Research Scientist, Centocor Research and Development
- Genetically Modified Animal Models and Safety Testing
Sandra J. Engle, Ph.D., Senior Principal Scientist, Genetically Modified Models Center of Emphasis, Pfizer Inc.
- Opportunities and Challenges of Biomarker Assays in Drug Development
Francois Legay, Ph.D., Global Head of Marker Localization and Assay, Novartis, Inc.